WO2022086300A1 - 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트 - Google Patents
외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트 Download PDFInfo
- Publication number
- WO2022086300A1 WO2022086300A1 PCT/KR2021/014976 KR2021014976W WO2022086300A1 WO 2022086300 A1 WO2022086300 A1 WO 2022086300A1 KR 2021014976 W KR2021014976 W KR 2021014976W WO 2022086300 A1 WO2022086300 A1 WO 2022086300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- genetic material
- target tissue
- vaccine composition
- antigen
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 83
- 108091007433 antigens Proteins 0.000 title claims abstract description 66
- 102000036639 antigens Human genes 0.000 title claims abstract description 63
- 239000000427 antigen Substances 0.000 title claims abstract description 59
- 229960005486 vaccine Drugs 0.000 title claims abstract description 53
- 210000001519 tissue Anatomy 0.000 claims description 59
- 241000700605 Viruses Species 0.000 claims description 44
- 239000013598 vector Substances 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108010065805 Interleukin-12 Proteins 0.000 claims description 19
- 102000013462 Interleukin-12 Human genes 0.000 claims description 19
- 241000710772 Yellow fever virus Species 0.000 claims description 18
- 210000001789 adipocyte Anatomy 0.000 claims description 17
- 229940051021 yellow-fever virus Drugs 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 241000710799 Rubella virus Species 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 10
- 230000006907 apoptotic process Effects 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 208000007514 Herpes zoster Diseases 0.000 claims description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 7
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000005549 size reduction Methods 0.000 claims description 6
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 6
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 5
- 108010002616 Interleukin-5 Proteins 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000034994 death Effects 0.000 claims description 3
- 239000000412 dendrimer Substances 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 2
- 238000011081 inoculation Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 16
- 235000020824 obesity Nutrition 0.000 abstract description 16
- 210000003207 subcutaneous adipocyte Anatomy 0.000 abstract description 2
- 210000000577 adipose tissue Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 229940021747 therapeutic vaccine Drugs 0.000 description 20
- 229940117681 interleukin-12 Drugs 0.000 description 16
- 235000021590 normal diet Nutrition 0.000 description 13
- 230000036039 immunity Effects 0.000 description 10
- 238000012937 correction Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000037237 body shape Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000004102 animal cell Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 101710172711 Structural protein Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- -1 fatty acid esters Chemical class 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960001515 yellow fever vaccine Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001126301 Echinostoma Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000498270 Necator americanus Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000170282 Absidia sp. (in: Fungi) Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241000244023 Anisakis Species 0.000 description 1
- 241000913828 Apios Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001327965 Clonorchis sinensis Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000498255 Enterobius vermicularis Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000244166 Hymenolepis diminuta Species 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001660197 Metagonimus Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241001480233 Paragonimus Species 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 235000012012 Paullinia yoco Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000952054 Rhizopus sp. Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 241000244157 Taenia solium Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000009643 reducing diet Nutrition 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a pharmaceutical composition for reducing the size or volume of a target tissue by inducing an immune response including a genetic material encoding a foreign antigen, and more particularly, to a therapeutic vaccine composition for preventing and/or treating obesity will be. More particularly, it relates to a composition that induces cell death constituting a target site by immunotherapy with an antigen gene.
- Obesity does not simply mean being overweight, but rather refers to a condition in which an excessive amount of body fat is accumulated in the body. is becoming Obesity, defined as excessive accumulation of fat, is accompanied by loss of adipose tissue metabolism, endocrine and immune function, and this pathological remodeling of adipose tissue is attracting attention as a pathophysiological factor of major metabolic diseases.
- a lipolytic enzyme inhibitor As a drug treatment for obesity, 'olistas', a lipolytic enzyme inhibitor, is used, which causes some of the fat in the body to be discharged out of the body, and side effects such as diarrhea and fatty stools appear.
- side effects such as diarrhea and fatty stools appear.
- side effects as well as decomposition of fat in unwanted parts of a woman's body.
- appetite suppressants that can be safely used, and bariatric surgery for the gastrointestinal tract may be helpful for highly obese patients with complications.
- the present invention is to provide a new method or pharmaceutical composition capable of reducing the size or volume of the target tissue by administration to the target tissue. More specifically, the method or pharmaceutical composition may be administered locally to a desired site to kill mast cells. Another embodiment is to provide a novel anti-obesity therapeutic agent or vaccine for treatment. The vaccine composition may be applied after at least one preliminary vaccine has been applied to the subject.
- the problem to be solved by the present invention is to provide a new type of anti-obesity therapeutic agent or vaccine for resolving only local obesity and completing a smooth body line.
- the problem to be solved by the present invention is that the immune system attacks adipocytes expressing antigenic protein and helps to kill adipocytes, thereby killing adipocytes, but not affecting adipocytes in unwanted areas. would like to provide
- One embodiment of the present invention administers a genetic material encoding an antigen derived outside the human body to a target tissue, and when the antigen gene is expressed in cells constituting the target tissue by the administered genetic material, pre-existing for this
- a pharmaceutical composition preferably a vaccine composition
- reducing tissue size or volume of a new concept, in which immunity acts to kill the cells and more specifically to provide a vaccine for preventing or treating obesity or a composition for removing subcutaneous fat cells do.
- One embodiment of the present invention administers a genetic material encoding an antigen derived outside the human body to a target tissue, and when the antigen gene is expressed in cells constituting the target tissue by the administered genetic material, pre-existing for this It provides a method of reducing tissue size or volume of a new concept, in which immunity acts to kill the cell.
- the inventors of the present invention have completed the present invention by confirming that the tissue constituting the cells can be reduced by killing the cells constituting the target site using an immune response.
- the present invention it was confirmed through an experiment that it is possible to achieve effective removal and/or reduction of fat cells, and through this, body shape correction and obesity treatment effects can be exhibited.
- One embodiment of the present invention is a pharmaceutical composition for reducing the tissue by administration to a target tissue, wherein the composition includes a genetic material encoding a foreign antigen.
- One embodiment of the present invention provides the use of target cell death and target tissue reduction of a genetic material encoding a foreign antigen, and more specifically, the use of the genetic material for local adipose tissue reduction.
- the genetic material encoding the foreign antigen is any one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or an epitope thereof.
- One embodiment may provide the use of target cell death or target tissue reduction of the virus or its epitope.
- the tissue is not particularly limited, and for example, includes a tissue consisting of any one or more cells selected from the group consisting of adipocytes, muscle cells, bone cells, chondrocytes, skin cells, secretory cells, and blood cells, preferably the The tissue may be adipose tissue or muscle tissue, and more preferably subcutaneous adipose tissue.
- the composition may induce reduction or death of adipocytes, particularly adipocytes distributed in subcutaneous fat.
- the inventors of the present invention have fewer side effects compared to conventional fat removal surgery and drugs, and provide a composition or kit that can be expected to have a body correction effect by targeting only a local target area (eg, adipose tissue in a specific area) .
- the present invention provides a pharmaceutical composition for reducing the size or volume of a target tissue by using immunotherapy that acts locally on a target site.
- the present invention preferably provides a pharmaceutical composition, a vaccine composition, or a therapeutic vaccine composition that induces apoptosis of adipocytes, particularly subcutaneous adipocytes.
- target tissue or target region refers to a cell population having the same structure and function to reduce size or volume.
- body correction or body shape correction means that the size or volume of the tissue is reduced by killing or reducing the cells constituting the tissue (eg, adipose tissue) accumulated in the unwanted area to have an externally slim effect. it means.
- locally acting means apoptosis or tissue size or It means bringing a volume reduction effect, and preferably can bring the effect within a range of 3 cm.
- the immune cells When an individual is exposed to an antigen, the immune cells function as phagocytosis and antigen presenting.
- the pharmaceutical composition of the present invention may be administered after an immune environment is created by intentionally or unintentionally infiltrating a foreign material such as a protein antigen, or an epitope thereof, into the body so that an immune response can be induced.
- the pharmaceutical composition may be repeatedly administered into the body.
- pre-existing immunity is induced by administering the genetic material contained in the pharmaceutical composition of the present invention to an individual, and then repeated administration of the composition results in monocytes, neutrophils, and lymphocytes in the human body. Natural killer cells, cytotoxic T cells, immune cells, physiologically active substances, antibodies, complement, etc.
- Adipose cells presented with the antigen by the substances secreted by the immune action die and the size of the adipose tissue Or the volume may be reduced.
- the composition may be used for body shape correction or body shape correction, and may be used for body shape correction in a local area.
- the composition may be administered to muscle tissue and used for skin wrinkle improvement effects such as Botox, body shape correction through muscle contraction, and the like.
- it can be used to remove benign or malignant tumors, or to remove warts on the skin.
- the pharmaceutical composition includes a genetic material encoding at least one antigen, and the genetic material includes not only DNA and/or RNA, but also antisense nucleotides, mRNA, ssRNA (single- stranded RNA) and cDNA.
- the antigen is a substance that causes an immune response to produce an antibody, and may include a tumor antigen, a virus, a bacteria, a protein, or an antigenic epitope.
- the antigen may be included without limitation as long as it can induce immunity, and the antigen includes, but is not limited to, non-human antigens, virus-derived antigens, bacterial-derived antigens, fungal-derived antigens, protozoan-derived antigens, It may be any one or more selected from the group consisting of avian-derived antigen, parasite-derived antigen, mycoplasma-derived antigen, and plant-derived antigen, and the antigen may be expressed as a peptide or an intact protein or a part thereof.
- Retroviridae eg human immunodeficiency virus such as HIV-1; Picornaviridae (eg polio virus, hepatitis A virus; enterovirus, human coxsackie) Viruses, rhinoviruses, echoviruses); Calciviridae (such as strains causing gastroenteritis); Togaviridae (such as equine encephalitis virus, rubella virus); Flaviridae (such as Dengue virus, encephalitis virus, yellow fever virus); Coronoviridae (eg coronavirus); Rhabdoviridae (eg bullous stomatitis virus, rabies virus); Filoviridae (eg Ebola) Virus); Paramyxoviridae (such as parainfluenza virus, parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (such as influenza virus); Bungavirid
- Non-limiting examples of bacterial-derived antigens include Pasteurella, Staphylococci, Streptococcus, Escherichia coli, Pseudomonas spp., and Salmonella spp. include Non-limiting examples of infectious bacteria include Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophilia, Mycobacteria spp (such as M. tuberculosis). (tuberculosis), M. avium, M. intracellulare, M. kansaii, M.
- Non-limiting examples of bacterial pathogens used in the present invention include: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Chlamydia pneumoniae, Legionella pneumophila, or Bordatella pertussis or any bacteria that are pathogenic in the lungs.
- Non-limiting examples of fungal-derived antigens include: Aspergillus fumigatus, Blastomyces sp., Coccidiodes immitis, Coccidiodes posadasi, Cryptococcus neoformans, Cryptococcus gatii, Fusarium.
- Sestodes wormworm
- Taenia saginata Taeniasolium
- Diphyllobotrium spp. Hymenolepis nana
- Hymenolepis diminuta examples of which include: Sestodes (wormworm), Taenia saginata, Taeniasolium, Diphyllobotrium spp.
- Hymenolepis nana Hymenolepis diminuta.
- Diphyllidium caninum Diphyllidium caninum, Nematodes (roundworm), A Ascaris rumbricoides, Stronggilloides stercoralis, Necator americanus, Ansilostoma duodenale, Ansilostomacaninium, Tichuli Stricura, Capilaria philippinensis, Trichostongilus spp., Tricinella spp., Necator americanus, Anisakis and related species, Angiostrongilus costarisensis, Enterobius vermicularis, Tremato Death (fluke), Faciolopsis buski, Heterophies species, Echinostoma species, Clonorchis sinensis, Officetorchis species, Fasiola species, Metagonimus yoko scissors, Shistozoma mansoni, Shisto and antigens derived from Zoma japonicum, Systozoma mekonggi, Systozoma intercal
- the tissue size reduction aspect may include any one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, rubella virus, influenza virus, mumps virus, and measles virus, preferably measles virus.
- the genetic material encoding the antigen may include a nucleic acid molecule having the nucleic acid sequence represented by SEQ ID NO: 1.
- the genetic material may include a nucleic acid molecule encoding a peptide having SEQ ID NO: 5 or 6.
- the genetic material may include a polynucleotide having a nucleic acid sequence having at least 85% sequence homology with SEQ ID NO: 1 and capable of reducing the target tissue size or volume (ie, capable of achieving the object of the present invention).
- the sequence homology may include 85% or more, 90% or more, 95% or more, 99% or more sequence homology.
- the sequence homology may include 85% or more, 90% or more, 95% or more, 99% or more sequence homology.
- the composition comprises IL-12, IL-2, IL-4, IL-5, IFN- ⁇ , IL-10, IL-1, IL-6, INF-alpha, INF-beta, TNF-alpha, and TNF- It may further include a genetic material encoding any one or more cytokines selected from the group consisting of beta, and it is preferable to include IL-12 in order to further maximize the immune stimulation effect by the antigen expressed by the genetic material. .
- the composition may be provided by including the genetic material in a vector for delivery in animal cells.
- the nucleic acid may be provided in an expression vector, such as a plasmid, etc.
- the nucleic acid may include transcription elements suitable for expression in a mammalian cell, such as a human cell.
- a "vector" can transport a genetic material to be administered into a cell.
- the vector can be used for genetic material delivery.
- such vectors may also comprise coding sequences operably linked to expression control sequences.
- the composition can be included in a plasmid (eg, gWiz TM vector) that enables protein expression in animal cells of a gene corresponding to a structural protein of the yellow fever virus (17D) gene.
- a plasmid eg, gWiz TM vector
- the yellow fever virus may be used without limitation, for example, the yellow fever virus may include the 17D strain, but is not limited thereto.
- the plasmid may include a nucleic acid molecule encoding a virus, or a fragment, variant or analog thereof. for example, SEQ ID NO: 1 or a fragment, variant, or analog thereof.
- the composition may include a gene corresponding to the structural protein of the rubella virus gene in a plasmid (eg, gWiz TM vector) that enables protein expression in animal cells.
- a plasmid eg, gWiz TM vector
- the rubella virus may be used without limitation, for example, the rubella virus may include, but is not limited to, strain RA27/3.
- the gene encoding the virus may include a gene encoding spike glycoproteins. Examples of the spike glycoprotein may include an E2-E1 heterozygote. For example, it may include a nucleic acid molecule encoding the protein of SEQ ID NO: 5 or a fragment, variant or analog thereof.
- the composition may include a plasmid (eg, gWiz TM vector) that allows a gene corresponding to a structural protein of a varicella zoster virus gene to be expressed in animal cells.
- a plasmid eg, gWiz TM vector
- the herpes zoster virus may be used without limitation, for example, the herpes zoster virus may include Oka strain, but is not limited thereto.
- the nucleic acid molecule encoding the virus may include a nucleic acid molecule encoding the surface protein gE protein. For example, it may include a nucleic acid molecule encoding the protein of SEQ ID NO: 6 or a fragment, variant or analog thereof.
- fragment, variant or analog thereof' means that the protein, peptide, nucleic acid, nucleic acid molecule, or gene of the present invention achieves the purpose to be achieved, but the sequence homology is 85% or more, 90% or more, 95% or more, It may be understood to mean a part of a protein, peptide, nucleic acid, nucleic acid molecule, or gene, which may be greater than or equal to 99%.
- including the fragment, variant or analog is meant to include a nucleic acid molecule of SEQ ID NO: 1, a nucleic acid molecule encoding SEQ ID NO: 5, or a nucleic acid molecule encoding SEQ ID NO: 6; Or, if the protein encoded by the nucleic acid molecule can achieve the objective, it can be understood as meaning that it is not excluded from the scope of the present invention.
- the foreign genetic material of the present application may preferably include genetic material derived from a virus, and the virus may preferably include yellow fever virus, rubella virus, and/or herpes zoster virus.
- the virus may be excellent in the effect of killing target tissue, preferably adipocytes, and reducing the size of the tissue. In addition, the effect can appear quickly and there are few side effects. In addition, even if stored for a long time as an injection, there is little risk of deterioration.
- the composition may further enhance the effect of apoptosis of adipocytes or target tissue shrinkage by including an immune enhancer capable of enhancing a cellular immune response.
- the composition may further include a genetic material encoding an immune enhancer capable of enhancing the immune enhancing effect, for example, an auxiliary genetic material encoding interleukin 12 (IL-12).
- the auxiliary genetic material may be provided by, for example, inserting a coding region into the pSF-CMV-CMV-Sbfl vector.
- the composition of the present invention may be used together with the above cytokines, genes encoding them or other adjuvants, as well as pharmaceutical carriers or excipients widely used in the art.
- the composition is formulated for human or veterinary use. It can be administered by various routes.
- the route of administration may be, but is not limited to, oral, transdermal, intramuscular, peritoneal, intravenous, subcutaneous, and nasal routes. More preferably, transdermal, muscle, peritoneal, or subcutaneous routes may be used.
- the composition may be administered by any device or route through which the active material can move to the target cell, and the composition of the present invention or the genetic material contained in the composition may be delivered to the target tissue or cells constituting the tissue.
- the administration method is not particularly limited.
- it may be formulated and provided as an injection, a microneedle patch, or the like.
- the injection is an aqueous solvent such as physiological saline solution and Ringel's solution, vegetable oil, higher fatty acid esters (eg, ethyl oleate), alcohols (
- it can be prepared using a non-aqueous solvent such as ethanol, benzyl alcohol, propylene glycol, glycerin, etc.) , tocopherol, EDTA, etc.), emulsifiers, buffers for pH control, and preservatives to inhibit the growth of microorganisms (eg, phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.) may include
- the microneedle may include both insoluble and soluble microneeds
- the genetic material and/or auxiliary genetic material included in the composition may be delivered into the body according to a conventional gene delivery method in the art.
- gene delivery methods include physical delivery methods such as electroporation or gene guns, lipid-DNA complexes (Lipoplex), polymer-DNA complexes (Polyplex), liposomes, and dendrimers. Chemical delivery methods such as dendrimers, nanoparticles, or other suitable transfer vectors may all be used.
- composition of the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount refers to an amount sufficient for the composition to exhibit therapeutic, ameliorating, or preventive effects, or to exhibit a vaccine effect, and not to cause side effects or serious or excessive immune response. it means.
- the composition of the present invention may be administered with a genetic material due to its purpose of inducing an immune response and inducing apoptosis, and it is preferable to administer it 4-8 times, preferably 5 times, with an interval of 2-3 days. When administered as described above, it is possible to obtain the effect of tissue reduction or shrinkage by apoptosis of the target site. As the composition is administered in large amounts or multiple times, there may be a difference in the apoptosis effect, and an appropriate dosage may be adjusted for each site.
- Another embodiment of the present invention reduces or reduces the size or volume of a tissue comprising administering a genetic material encoding a protein antigen, a vector comprising the genetic material, or a composition comprising them to a target tissue of an individual provides a way to The method is preferably capable of killing cells constituting the subcutaneous adipose tissue.
- the i) method or ii) the genetic material encoding the protein antigen, the vector comprising the genetic material, or a composition comprising them, or a kit comprising the same is used for improving or treating obesity in an individual, wrinkle improvement use , for muscle reduction, for removing or reducing benign or malignant tumors, for removing warts, etc., for cosmetic purposes, for removing fat pockets under the eyes, and for alleviating dark circles.
- wrinkle improvement use for muscle reduction, for removing or reducing benign or malignant tumors, for removing warts, etc.
- cosmetic purposes for removing fat pockets under the eyes, and for alleviating dark circles.
- the method may further include the step of creating an immune environment in the body before administering the genetic material, the vector including the genetic material, or a composition including them to the target tissue.
- the step of creating an immune environment in the body may include administering a foreign substance capable of inducing an immune response.
- the foreign material may be included without limitation as long as it is a material using a protein as an antigen.
- One embodiment of the present invention may be provided not only for treatment, improvement, or prevention of various indications, but also for cosmetic purposes for improvement of appearance.
- kits for reducing the target tissue size or volume, comprising a genetic material encoding a foreign antigen; And (b) provides a kit comprising an administration instruction for administering the vaccine.
- the kit (c) may further include a composition comprising a protein antigen or an epitope thereof for the composition of an immune environment prior to administration of the composition (a).
- (c) may be understood as at least one or more pre-vaccine or a composition for inducing an immune response.
- the 'pre-vaccine' mentioned herein may be understood as a vaccine administered before the vaccine composition for reducing the target tissue size or volume of the present application is administered, and a vaccine for reducing the target tissue size or volume of the present application to obtain pre-existing immunity It may be understood as a vaccine composition administered before the composition is administered.
- the prior vaccine may contain the same antigenic material as the antigenic material included in the vaccine composition for reducing the target tissue size or volume of the present application.
- a vaccine composition for reducing target tissue size or volume, including genetic material encoding a foreign antigen may include yellow fever virus, rubella virus, and/or herpes zoster virus, (c) also yellow fever virus, rubella virus, and/or herpes zoster virus.
- the (a) vaccine composition may further include a genetic material encoding a cytokine, and materials that can be used to increase the immune effect of the (a) composition may be included without limitation.
- the cytokines are IL-12, IL-2, IL-4, IL-5, IFN- ⁇ , IL-10, IL-1, IL-6, INF-alpha, INF-beta, TNF-alpha, and TNF - May include any one or more selected from the group consisting of beta.
- kits of the present invention may comprise at least one additional agent as defined herein in relation to the pharmaceutical composition, antimicrobial agent, DNase inhibitor RNase inhibitor, solubilizer and the like.
- a kit may, for example, consist of one or more kit parts (eg, a container).
- each container may be in a syringe, prefilled syringe, vial, bottle, jar, sealed sleeve, envelope or pouch, tube or blister package or any other suitable form in which the container is configured to prevent premature mixing of the components.
- Each of the different components may be provided separately, or some of the different components may be provided together (ie, in the same container).
- the kit may also include administration instructions having information on administration, administration method and dosage of any component.
- Another embodiment of the present invention provides a syringe filled with a vaccine composition for reducing the size or volume of a target tissue, including a genetic material encoding a foreign antigen.
- the syringe may further include a genetic material encoding a cytokine.
- the cytokines are IL-12, IL-2, IL-4, IL-5, IFN- ⁇ , IL-10, IL-1, IL-6, INF-alpha, INF-beta, TNF-alpha, and TNF - May include any one or more selected from the group consisting of beta.
- the present invention provides a novel composition for improving or treating obesity, which can kill cells of a specific target region, and can reduce or reduce the size or volume of a tissue.
- a body shape correction effect or a body shape improvement effect can be obtained.
- the present invention can provide a new type of anti-obesity treatment capable of resolving only topical obesity and completing a smooth body line.
- the therapeutic agent for obesity of the present invention can selectively reduce only the tissue of a desired site, and does not affect the tissue of the unwanted site or cells constituting the same, and is effective for selective reduction of the local area.
- composition of the present invention can be used for cosmetic purposes for improving the appearance.
- NC denotes a normal mouse to which nothing was administered
- ND Normal diet
- HFD High fat diet
- Adipose tissue (AT) after administration of a therapeutic vaccine.
- FIG. 4 shows a statistical analysis result of a weight change rate of adipose tissue (AT).
- MOCK/therapeutic agent therapeutic vaccine
- MOCK/therapeutic agent + IL-12 was P-VALUE 0.0005.
- 5 is a structural protein (capsid protein, prM protein, envelope protein, 119 ⁇ 2452 bp (2334 bp)) in the genome (GenBank: X03700.1) of Yellow fever virus (17D) encoding a genetic material (SEQ ID NO: 1) Shows the vector map inserted into gWiz TM vector. tga (stop codon) was added at the end.
- IL-12 p35 is a restriction enzyme at MCS site I; It was inserted into EcoRI and XhoI sites, and IL-12 p40 was a restriction enzyme at MCS site II; It was inserted at the SalI and SpeI sites.
- a genetic material for administration to an individual from which pre-existing immunity is induced and an immune enhancer that can be administered together with the genetic material were prepared as follows.
- a genetic material encoding SEQ ID NO: 5, encoding E1-E2 protein of RA27/3 strain of Rubella virus was prepared.
- a genetic material encoding the gE protein in the Oka strain of Varicella zoster virus encoding SEQ ID NO: 6 was prepared.
- the vector map is shown in FIG. 5 .
- SEQ ID NOs: 2 and 3 which are nucleic acid sequences corresponding to the coding regions (p35; 127-774bp, p40; 35-1042bp) of p35 (GenBank: M86672.1) and p40 (GenBank: M86671.1) of IL-12, respectively It was inserted into the pSF-CMV-CMV-Sbfl vector together with the kozak sequence.
- the vector map is shown in FIG. 6 .
- the kozak sequence is inserted at the front of each IL-12 synthesis.
- the cloned YF-antigen plasmid and mIL12-plasmid are transformed into DH5a competent cells.
- the cells were mass-cultured and plasmids were recovered using a plasmid prep kit.
- Formation of pre-existing immunity was induced using live attenuated virus, a vaccine strain virus. 17D virus was used as the vaccine strain virus.
- 17D virus live attenuated virus
- 17D virus live attenuated virus
- blood was collected and serum was isolated.
- Antibodies specific for YFV were detected from the separated serum through ELISA analysis.
- 17D virus used for injection was coated on a plate at a concentration of 5 x 10 4 pfu/well, and the assay sample (serum) was diluted and reacted for 2 h. After washing, the anti-mouse IgG-HRP secondary antibody was diluted 1/4000 and the reaction was carried out for 2 h. After washing, a coloring solution was added and reacted for 10 min to measure the OD value.
- mice or obese-induced mice were divided into a group to which yellow fever vaccine was administered and a group to which they were not administered, respectively, and used in the experiment. All mice were given a normal diet from 3 days before administration of the therapeutic vaccine.
- mice were divided into left and right and injected into two sites: inguinal adipose tissue and interscapular adipose tissue on one side. It was administered 5 times with an interval of 2-3 days, and the antigen DNA was 100ug/site, and the IL-12 DNA was 50ug/site, and a total of 150ug/site was used, and an empty vector was used according to the total amount of antigen DNA administered.
- Body weights were measured before and after administration of the therapeutic vaccine. Seven days after the last therapeutic vaccine administration, mice were dissected, inguinal adipose tissue and interscapular adipose tissue were separated, and each weight was measured.
- ND Normal diet
- HFD 60% high fat diet
- the average change rate of body weight and the effect of reducing adipose tissue after administration of the treatment for each group in Table 1 were confirmed, respectively, and shown in FIGS. 2 to 4 .
- the body weight was measured before and after administration of the therapeutic vaccine (therapeutic agent, treatment), and the change in body weight was measured based on the body weight immediately before administration.
- Both the vaccine 1 and therapeutic vaccine 2 groups showed an effect of reducing body weight, and the groups administered with the therapeutic vaccine 1 and 2 decreased significantly.
- the weight loss was the greatest.
- Figure 3 shows the weight of AT by separating inguinal AT (adipose tissue) and interscapular AT from the left and right sides of the mouse on the 7th day after administration of the therapeutic vaccine 5 times, and the empty vector or therapeutic vaccine is not administered in the same subject Shows the results of comparing the amount of fat weight loss based on AT. It can be seen that adipose tissue weight decreased when treated with therapeutic vaccines 1 and 2 when compared with the control and empty vector administration groups to which nothing was administered. In particular, it can be seen that the change in adipose tissue weight was much larger in the treatment vaccine 2 treatment group administered with IL-12.
- the present invention may prevent and/or treat obesity.
- the present invention provides a method for preventing and/or treating obesity by local injection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
그룹 | Obesity | Diet 1 | Diet 2 | Basal immunity(3차) | Obese vaccine(5차) | Interval | 개체 수 |
Control 1 | Normal | ND | ND | 배지 | - | - | 5 |
Control 2 | Normal | ND | ND | YF vaccine 접종 | - | - | 5 |
Mock | DIO | HFD | ND | YF vaccine 접종 | Empty vector | 2일 | 10 |
치료용 백신 1 | HFD | ND | YF vaccine 접종 | 항원 DNA (서열번호 1) | 2일 | 10 | |
치료용 백신 2 | HFD | ND | YF vaccine 접종 | 항원 DNA (서열번호 1) + IL12 DNA (서열번호 2 및 3) | 2일 | 10 |
Claims (23)
- 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 타겟 조직은 지방세포, 근육세포, 골세포, 연골세포, 피부세포, 분비세포 및 혈세포로 이루어진 군에서 선택된 어느 하나 이상의 세포로 이루어진 조직인 것을 특징으로 하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 약학 조성물은 지방 세포의 감소 또는 사멸을 유도하는 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 조성물에 포함되는 외래 항원은 비인간 유래 항원, 바이러스 유래 항원, 세균 유래 항원, 진균 유래 항원, 원생동물 유래 항원, 조류 유래 항원, 기생충 유래 항원, 마이코플라즈마 유래 항원, 및 식물 유래 항원으로 이루어진 군에서 선택되는 어느 하나 이상인 것을 특징으로 하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제4항에 있어서, 상기 외래 항원은 황열 바이러스, 대상포진 바이러스, 및 풍진 바이러스로 이루어진 군에서 선택된 어느 하나 이상의 바이러스; 또는 이들의 에피토프인 것을 특징으로 하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 유전물질은 DNA 또는 RNA인 것을 특징으로 하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 유전물질은 서열번호 1의 핵산분자; 및 서열번호 5 또는 6의 펩타이드를 암호화하는 핵산분자로 이루어진 군에서 선택된 어느 하나 이상을 포함하는 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 백신 조성물은 사이토카인을 코딩하는 유전물질을 더 포함하는 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제8항에 있어서, 상기 사이토카인은 IL-12, IL-2, IL-4, IL-5, IFN-γ, IL-10, IL-1, IL-6, INF-알파, INF-베타, TNF-알파, 및 TNF-베타로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 하는 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 외래 항원은 세포 내 면역 반응을 유발하는 것을 특징으로 하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 조성물은 국소적으로 작용하며,상기 백신 조성물은 적어도 1종 이상의 면역 환경 조성을 위한 단백질 또는 이의 에피토프가 먼저 개체에 적용된 후에 적용되는 것을 특징으로 하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 유전물질은 경구, 경피, 근육, 복막, 정맥, 피하, 또는 비강 경로를 통한 주사, 또는전기천공법, 유전자총, 리포좀, 덴드리머들(dendrimers), 나노입자들(nanoparticles), 또는 이동(transfer) 벡터를 통하여 타겟 조직에 투여되는 것을 특징으로 하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- 제1항에 있어서, 상기 조성물에 포함된 유전물질의 투여량은 1회 접종 시 0.1~1000ug/site 되는 것을 특징으로 하는 타겟 조직 크기 또는 부피 축소용 백신 조성물.
- (a) 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물; 및(b) 상기 백신 투여를 위한 투여지침서를 포함하는, 키트.
- 제14항에 있어서,상기 키트는 (c) 상기 (a) 조성물 투여 전에 면역 환경 조성을 위한 단백질 항원 또는 이의 에피토프를 포함하는 조성물이 더 포함된, 키트.
- 제14항에 있어서, 상기 (a) 백신 조성물은 사이토카인을 코딩하는 유전물질을 더 포함하는 키트.
- 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직 크기 또는 부피 축소용 백신 조성물이 충전된 시린지.
- 제17항에 있어서, 상기 시린지는 사이토카인을 코딩하는 유전물질을 더 포함하는 시린지.
- 적어도 하나의 외래 항원을 코딩하는 유전물질을 포함하는 피하 지방 세포 제거용 조성물.
- 제19항에 있어서, 상기 조성물은 사이토카인을 코딩하는 유전물질을 더 포함하는 피하 지방 세포 제거용 조성물.
- 개체의 타겟 조직 크기 또는 부피의 축소 방법으로,외래 항원을 코딩하는 유전물질을 개체의 타겟 조직에 투여하는 단계를 포함하는 방법.
- 제21항에 있어서, 상기 방법은 개체의 지방 세포의 감소 또는 사멸을 유도하는 것을 특징으로 하는 방법.
- 제21항에 있어서, 상기 방법은 IL-12, IL-2, IL-4, IL-5, IFN-γ, IL-10, IL-1, IL-6, INF-알파, INF-베타, TNF-알파, 및 TNF-베타로 이루어진 군에서 선택된 어느 하나 이상의 사이토카인을 동시에 또는 순차적으로 투입하는 단계를 포함하는 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3196320A CA3196320A1 (en) | 2020-10-23 | 2021-10-22 | Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen |
EP21883367.1A EP4233897A1 (en) | 2020-10-23 | 2021-10-22 | Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen |
JP2023524776A JP2023546603A (ja) | 2020-10-23 | 2021-10-22 | 外来抗原をコードする遺伝物質を含む、ターゲット組織の大きさまたは体積の縮小用のワクチン組成物またはキット |
AU2021364852A AU2021364852A1 (en) | 2020-10-23 | 2021-10-22 | Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen |
CN202180086540.4A CN116635060A (zh) | 2020-10-23 | 2021-10-22 | 包含编码外来抗原的遗传物质的用于减小靶组织的尺寸或体积的疫苗组合物或药盒 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0138615 | 2020-10-23 | ||
KR20200138615 | 2020-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022086300A1 true WO2022086300A1 (ko) | 2022-04-28 |
Family
ID=81289999
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/014976 WO2022086300A1 (ko) | 2020-10-23 | 2021-10-22 | 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트 |
PCT/KR2021/014977 WO2022086301A1 (ko) | 2020-10-23 | 2021-10-22 | 황열 바이러스를 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/014977 WO2022086301A1 (ko) | 2020-10-23 | 2021-10-22 | 황열 바이러스를 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4233897A1 (ko) |
JP (1) | JP2023546603A (ko) |
KR (1) | KR20220054225A (ko) |
CN (1) | CN116635060A (ko) |
AU (1) | AU2021364852A1 (ko) |
CA (1) | CA3196320A1 (ko) |
WO (2) | WO2022086300A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023204693A1 (ko) * | 2022-04-22 | 2023-10-26 | 에스케이바이오사이언스 주식회사 | 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020082271A (ko) * | 2001-04-20 | 2002-10-31 | 허만욱 | 비만 억제 폴리펩타이드 |
KR20050093280A (ko) * | 2004-03-18 | 2005-09-23 | (주)에스제이바이오메드 | 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물 |
WO2017170494A1 (ja) * | 2016-03-29 | 2017-10-05 | 国立大学法人東京大学 | 抗肥満ワクチン |
KR20180042284A (ko) * | 2015-08-11 | 2018-04-25 | 스템이뮨, 인코포레이티드 | 암 치료에 사용하기 위한 천연두 백신 |
KR20200138615A (ko) | 2019-06-01 | 2020-12-10 | 신승수 | 애완용목줄 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69824750T2 (de) * | 1997-10-31 | 2005-07-07 | Children's Medical Center Corp., Boston | Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe |
EP1471873A4 (en) * | 2002-01-15 | 2005-03-16 | Acambis Inc | VACCINES AGAINST FLAVIVIRUS |
KR20040062832A (ko) * | 2003-01-03 | 2004-07-09 | 학교법인 경희대학교 | 비만 치료 또는 예방용 및, 비만과 관련된 유전자,단백질, 세포 발현 조절용 한약 추출물을 포함하는약제학적 조성물 |
CA3150411C (en) * | 2009-07-31 | 2023-09-12 | Pnuvax Inc. | High yield yellow fever virus strain with increased propagation in cells |
CN115252910A (zh) * | 2017-10-18 | 2022-11-01 | 生命细胞公司 | 脂肪组织产品以及产生方法 |
-
2021
- 2021-10-22 AU AU2021364852A patent/AU2021364852A1/en active Pending
- 2021-10-22 WO PCT/KR2021/014976 patent/WO2022086300A1/ko active Application Filing
- 2021-10-22 CA CA3196320A patent/CA3196320A1/en active Pending
- 2021-10-22 WO PCT/KR2021/014977 patent/WO2022086301A1/ko not_active Application Discontinuation
- 2021-10-22 CN CN202180086540.4A patent/CN116635060A/zh active Pending
- 2021-10-22 KR KR1020210142198A patent/KR20220054225A/ko unknown
- 2021-10-22 EP EP21883367.1A patent/EP4233897A1/en active Pending
- 2021-10-22 JP JP2023524776A patent/JP2023546603A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020082271A (ko) * | 2001-04-20 | 2002-10-31 | 허만욱 | 비만 억제 폴리펩타이드 |
KR20050093280A (ko) * | 2004-03-18 | 2005-09-23 | (주)에스제이바이오메드 | 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물 |
KR20180042284A (ko) * | 2015-08-11 | 2018-04-25 | 스템이뮨, 인코포레이티드 | 암 치료에 사용하기 위한 천연두 백신 |
WO2017170494A1 (ja) * | 2016-03-29 | 2017-10-05 | 国立大学法人東京大学 | 抗肥満ワクチン |
KR20200138615A (ko) | 2019-06-01 | 2020-12-10 | 신승수 | 애완용목줄 |
Non-Patent Citations (1)
Title |
---|
DATABASE PROTEIN 23 February 2022 (2022-02-23), ANONYMOUS : "RecName: Full=Structural polyprotein; AltName: Full=p110; Contains: RecName: Full=Capsid protein; AltName: Full=Coat protein; Short=C; Contains: RecName: Full=Spike glycoprotein E2; AltName: Full=E2 envelope glycoprotein; Contains: RecName: Full=Spike glycopro... ", XP055923052, retrieved from NCBI Database accession no. P19725 * |
Also Published As
Publication number | Publication date |
---|---|
JP2023546603A (ja) | 2023-11-06 |
CN116635060A (zh) | 2023-08-22 |
WO2022086301A1 (ko) | 2022-04-28 |
AU2021364852A1 (en) | 2023-06-22 |
CA3196320A1 (en) | 2022-04-28 |
EP4233897A1 (en) | 2023-08-30 |
KR20220054225A (ko) | 2022-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2340532T3 (es) | Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo. | |
ES2328751T3 (es) | Liberacion de polipeptidos biologicamente activos. | |
Lee et al. | Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors | |
JPH06508039A (ja) | 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス | |
JP2000515521A (ja) | イヌの症状、特に呼吸器および消化器症状に対するポリヌクレオチドワクチン製剤 | |
WO2022086300A1 (ko) | 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트 | |
EP3210631A1 (en) | Dna vaccine composition for preventing and treating herpes zoster, and method for activating t cells for vzv antigen by using same | |
AU2017353323B2 (en) | Tolerogenic DNA vaccine | |
WO2018083111A1 (en) | Tolerogenic dna vaccine | |
WO2019139229A1 (en) | Microorganism for delivering drug for treatment of gastrointestinal disease, which expresses and secretes p8 protein, and pharmaceutical composition for preventing or treating gastrointestinal disease, which includes the same | |
WO2003031602A1 (fr) | Micro-organismes oncolytiques exprimant les proteines hsp, et leurs utilisations | |
JP4638880B2 (ja) | アルキルホスファチジルコリン配合ワクチン組成物 | |
JP4846598B2 (ja) | 弱毒化ウサギ粘液腫ウイルスに基づくモノ非特異的免疫誘導剤 | |
JP2004026802A (ja) | 人間あるいは動物体内の癌あるいは腫瘍を治療する薬物を製造する方法 | |
WO2023279771A1 (zh) | 一种抗多发性硬化的重组蛋白及其制备方法和用途 | |
JP2007534664A5 (ko) | ||
ES2267560T3 (es) | Secuencias de adn para mejorar la eficacia de alimentacion y la tasa de crecimiento en cerdos. | |
PT684842E (pt) | Composicao para o tratamento de tumores e para a imunizacao de organismos contra tumores | |
JPWO2008065752A1 (ja) | diRNAを有効成分とする免疫治療用薬剤 | |
KR100825984B1 (ko) | 조사된 인간 b형 간염 표면 항원을 발현하는 암세포를이용하여 종양을 치료하는 방법 및 상기 암세포를 포함하는종양치료용 약학적 조성물 | |
KR20230151488A (ko) | 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트 | |
WO2019149039A1 (zh) | 一种抗肿瘤蛋白质组合物及其应用 | |
US11479588B2 (en) | Cathelicidin-expressing lactic acid bacteria | |
AU729199B2 (en) | Composition for use in the treatment of tumours and the immunization of humans and animals | |
RU2154493C2 (ru) | Способ лечения паротитных орхитов у детей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21883367 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3196320 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023524776 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023007475 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023007475 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230420 |
|
ENP | Entry into the national phase |
Ref document number: 2021883367 Country of ref document: EP Effective date: 20230523 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180086540.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2021364852 Country of ref document: AU Date of ref document: 20211022 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523440402 Country of ref document: SA |